Crescent Biopharma, Inc. (“Crescent” or the “Company”), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, announces the completion of its previously announced merger with GlycoMimetics, Inc. (“GlycoMimetics”). The combined company will operate under the name Crescent Biopharma, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “CBIO.” Immediately prior to the closing of the merger, Crescent completed a previously announced private financing of $200 million in gross proceeds led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a large institutional investor, with participation from a broad syndicate of healthcare-focused investors.
Read the full article: Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200M //
Source: https://www.globenewswire.com/news-release/2025/06/16/3099691/0/en/Crescent-Biopharma-Completes-Closing-of-Merger-with-GlycoMimetics-and-Previously-Announced-Private-Placement-of-200-Million.html